1
|
Parra-Guillen ZP, Mangas-Sanjuan V, Garcia-Cremades M, Troconiz IF, Mo G, Pitou C, Iversen PW, Wallin JE. Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. J Pharmacol Exp Ther 2018; 366:96-104. [PMID: 29691287 DOI: 10.1124/jpet.118.248286] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Accepted: 04/16/2018] [Indexed: 12/21/2022] Open
Abstract
Xenograft mice are largely used to evaluate the efficacy of oncological drugs during preclinical phases of drug discovery and development. Mathematical models provide a useful tool to quantitatively characterize tumor growth dynamics and also optimize upcoming experiments. To the best of our knowledge, this is the first report where unperturbed growth of a large set of tumor cell lines (n = 28) has been systematically analyzed using a previously proposed model of nonlinear mixed effects (NLME). Exponential growth was identified as the governing mechanism in the majority of the cell lines, with constant rate values ranging from 0.0204 to 0.203 day-1 No common patterns could be observed across tumor types, highlighting the importance of combining information from different cell lines when evaluating drug activity. Overall, typical model parameters were precisely estimated using designs in which tumor size measurements were taken every 2 days. Moreover, reducing the number of measurements to twice per week, or even once per week for cell lines with low growth rates, showed little impact on parameter precision. However, a sample size of at least 50 mice is needed to accurately characterize parameter variability (i.e., relative S.E. values below 50%). This work illustrates the feasibility of systematically applying NLME models to characterize tumor growth in drug discovery and development, and constitutes a valuable source of data to optimize experimental designs by providing an a priori sampling window and minimizing the number of samples required.
Collapse
Affiliation(s)
- Zinnia P Parra-Guillen
- Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Navarra Institute for Health Research, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Global PK/PD & Pharmacometrics (G.M., C.P., J.E.W.) and Lilly Research Laboratories (P.W.I.), Eli Lilly and Company, Indianapolis, USA Solna, Sweden
| | - Victor Mangas-Sanjuan
- Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Navarra Institute for Health Research, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Global PK/PD & Pharmacometrics (G.M., C.P., J.E.W.) and Lilly Research Laboratories (P.W.I.), Eli Lilly and Company, Indianapolis, USA Solna, Sweden
| | - Maria Garcia-Cremades
- Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Navarra Institute for Health Research, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Global PK/PD & Pharmacometrics (G.M., C.P., J.E.W.) and Lilly Research Laboratories (P.W.I.), Eli Lilly and Company, Indianapolis, USA Solna, Sweden
| | - Iñaki F Troconiz
- Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Navarra Institute for Health Research, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Global PK/PD & Pharmacometrics (G.M., C.P., J.E.W.) and Lilly Research Laboratories (P.W.I.), Eli Lilly and Company, Indianapolis, USA Solna, Sweden
| | - Gary Mo
- Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Navarra Institute for Health Research, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Global PK/PD & Pharmacometrics (G.M., C.P., J.E.W.) and Lilly Research Laboratories (P.W.I.), Eli Lilly and Company, Indianapolis, USA Solna, Sweden
| | - Celine Pitou
- Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Navarra Institute for Health Research, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Global PK/PD & Pharmacometrics (G.M., C.P., J.E.W.) and Lilly Research Laboratories (P.W.I.), Eli Lilly and Company, Indianapolis, USA Solna, Sweden
| | - Philip W Iversen
- Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Navarra Institute for Health Research, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Global PK/PD & Pharmacometrics (G.M., C.P., J.E.W.) and Lilly Research Laboratories (P.W.I.), Eli Lilly and Company, Indianapolis, USA Solna, Sweden
| | - Johan E Wallin
- Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Navarra Institute for Health Research, Pamplona, Spain (Z.P.P.-G.,V.M.-S.,M.G.-C., I.F.T.); Global PK/PD & Pharmacometrics (G.M., C.P., J.E.W.) and Lilly Research Laboratories (P.W.I.), Eli Lilly and Company, Indianapolis, USA Solna, Sweden
| |
Collapse
|
2
|
Chigutsa E, Long AJ, Wallin JE. Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients. CPT Pharmacometrics Syst Pharmacol 2017; 6:560-568. [PMID: 28569042 PMCID: PMC5572351 DOI: 10.1002/psp4.12209] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Revised: 05/12/2017] [Accepted: 05/15/2017] [Indexed: 12/24/2022]
Abstract
We sought to describe the exposure-response relationship of necitumumab efficacy in squamous non-small cell lung cancer patients and evaluate intrinsic and extrinsic patient descriptors that may guide dosing. SQUIRE was a phase III study comparing necitumumab in combination with gemcitabine and cisplatin vs. gemcitabine and cisplatin alone in 1,014 patients. An integrated model for tumor size dynamics and overall survival was developed, where reduction in tumor size results in a decrease in survival hazard. The change in tumor size was characterized using linear growth and first-order shrinkage. Overall survival was described using a combination of a Weibull function and Gompertz function for the hazard, with dynamic tumor size being a predictor for the hazard. Although body weight resulted in higher clearance and lower exposure, simulations showed that an 800 mg flat dose provided optimal response regardless of body weight.
Collapse
Affiliation(s)
- E Chigutsa
- PKPD&Pharmacometrics, Eli Lilly, Indianapolis, Indiana, USA
| | - A J Long
- PKPD&Pharmacometrics, Eli Lilly, Indianapolis, Indiana, USA
| | | |
Collapse
|
4
|
Wallin JE, Friberg LE, Karlsson MO. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol 2009; 106:234-42. [PMID: 20050841 DOI: 10.1111/j.1742-7843.2009.00520.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
One of the most employed approaches to reduce severe neutropenia following anticancer drug regimens is to reduce the consecutive dose in fixed steps, commonly by 25%. Another approach has been to use pharmacokinetic (PK) sampling to tailor dosing, but only rarely have model-based computer approaches utilizing collected PK and/or pharmacodynamic (PD) data been used. A semi-mechanistic model for myelosuppression that can characterize the interindividual and interoccasion variability in the time-course of neutrophils following administration of a wide range of anticancer drugs may be used in a clinical setting for model-based dose individualization. The aim of this study was to compare current stepwise procedures to model-based dose adaptation by simulations, and investigate if the overall dose intensity in the population could be increased without increasing the risk of severe toxicity. The value of various amounts of PK- and/or PD-information was compared to standard dosing strategies using a maximum a posteriori procedure in NONMEM. The results showed that when information on neutrophil counts was available, the additional improvement from PK sampling was negligible. Using neutrophil sampling at baseline and an observation near the predicted nadir increased the number of patients in the target range by 27% in comparison with a one-sided 25% dose adjustment schedule, while keeping the number of patients experiencing severe toxicity at a comparable low level after five courses of treatment. High interindividual variability did not limit the benefit of model-based dose adaptation, whereas high interoccasion variability was predicted to make any dose adaptation method less successful. This study indicates that for successful model-based dose adaptation clinically, there is no need for drug concentration sampling, and that one extra neutrophil measurement in addition to the pre-treatment value is sufficient to limit severe neutropenia while increasing dose intensity.
Collapse
Affiliation(s)
- Johan E Wallin
- Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
| | | | | |
Collapse
|